Janux Therapeutics Inc’s recently made public that its Director Lichter Jay unloaded Company’s shares for reported $82.12 million on Jun 03 ’24. In the deal valued at $54.75 per share,1,500,000 shares were sold. As a result of this transaction, Lichter Jay now holds 633,673 shares worth roughly $24.56 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Reardon Tighe sold 822,721 shares, generating $45,043,975 in total proceeds. Upon selling the shares at $54.75, the Acting Chief Financial Officer now owns 633,673 shares.
Before that, Avalon Ventures XI, L.P. sold 822,721 shares. Janux Therapeutics Inc shares valued at $45,043,975 were divested by the 10% Owner at a price of $54.75 per share. As a result of the transaction, Avalon Ventures XI, L.P. now holds 633,673 shares, worth roughly $24.56 million.
Scotiabank initiated its Janux Therapeutics Inc [JANX] rating to a Sector perform in a research note published on May 30, 2024; the price target was $47. A number of analysts have revised their coverage, including BTIG Research’s analysts, who began to cover the stock in late March with a ‘”a Buy”‘ rating. Cantor Fitzgerald began covering JANX with “an Overweight” recommendation on March 20, 2024. Wedbush started covering the stock on April 06, 2023. It rated JANX as “an Outperform”.
Price Performance Review of JANX
On Friday, Janux Therapeutics Inc [NASDAQ:JANX] saw its stock fall -6.51% to $38.76. Over the last five days, the stock has lost -11.89%. Janux Therapeutics Inc shares have risen nearly 261.23% since the year began. Nevertheless, the stocks have risen 203.52% over the past one year. While a 52-week high of $65.60 was reached on 05/03/24, a 52-week low of $5.65 was recorded on 02/05/24. SMA at 50 days reached $43.39, while 200 days put it at $28.73. A total of 0.6 million shares were traded, compared to the trading of 0.42 million shares in the previous session.
Levels Of Support And Resistance For JANX Stock
The 24-hour chart illustrates a support level at 37.91, which if violated will result in even more drops to 37.06. On the upside, there is a resistance level at 39.86. A further resistance level may holdings at 40.97. The Relative Strength Index (RSI) on the 14-day chart is 39.93, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -3.09, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 94.43%. Stochastics%K at 8.18% indicates the stock is a buying.
The most recent change occurred on November 14, 2022 when William Blair began covering the stock and recommended ‘”an Outperform”‘ rating .
